Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

RegulatoryapprovedSIL204Positive

AI Analysis

Summary

Silexion Therapeutics received approval from Germany's BfArM to initiate a Phase 2/3 clinical trial for SIL204 in patients with locally advanced pancreatic cancer. This regulatory milestone allows the company to advance its oncology candidate into a combined Phase 2/3 study.

Clinical Trial Data

Phase

2/3

Outcome Details

Approval received from Germany's BfArM to initiate Phase 2/3 clinical trial

Importance:6/10

Sentiment:

0.70

clinical_trialregulatory_approvaloncologypancreatic_cancerPhase_2/3

Related Companies

$SLXN

Read the original article

Published by yahoo_finance on June 23, 2026 12:40 PM

Read Original